Rapamycin (low-dose, weekly)

Low-dose weekly rapamycin is a compound being explored for its potential anti-aging effects and health benefits in various animal models and preliminary human trials. Studies indicate that low-dose, weekly administration of rapamycin can improve heart function and reduce hypertrophy in cats with cardiomyopathy without significant side effects. In humans, the PEARL trial found that a year of treatment was safe and showed some positive impacts on healthspan metrics like blood pressure and cholesterol levels. The compound has also been tested in dogs, showing no adverse cardiac effects at low doses. Connections to cardiovascular health and longevity research are strong, given rapamycin's impact on heart function and its potential role in extending healthy lifespan. While the evidence is promising, it remains early, with most studies conducted on animals or small human trials, limiting broad conclusions about long-term safety and efficacy.

Sources

• Delayed-release rapamycin halts progression of left ventricular hypertrophy in subclinical feline hypertrophic cardiomyopathy: results of the RAPACAT trial. (PMID:37495229)
• Influence of rapamycin on safety and healthspan metrics after one year: PEARL trial results. (PMID:40188830)
• Multi-Omic, Histopathologic, and Clinicopathologic Effects of Once-Weekly Oral Rapamycin in a Naturally Occurring Feline Model of Hypertrophic Cardiomyopathy: A Pilot Study. (PMID:37893908)
• A masked, placebo-controlled, randomized clinical trial evaluating safety and the effect on cardiac function of low-dose rapamycin in 17 healthy client-owned dogs. (PMID:37275618)
• Phase II multicentered study of low-dose everolimus plus cisplatin and weekly 24-hour infusion of high-dose 5-fluorouracil and leucovorin as first-line treatment for patients with advanced gastric cancer. (PMID:25011938)
• A phase I study of daily everolimus plus low-dose weekly cisplatin for patients with advanced solid tumors. (PMID:21913034)

_Worker-drafted node, Hermes writer enrichment, pending editorial review._